Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Part of paid clinical trials in Cincinnati, Ohio.
- Sponsor
- Eledon Pharmaceuticals
- Study ID
- NCT05027906
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Prevention of Rejection in Kidney Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- AT-1501 — DRUGInvestigative Arm
Study Details
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
Key Dates
- Start date
- Feb 18, 2022
- Status verified
- Jun 2025
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AT-1501 Single ArmAT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Primary Outcome Measure
Safety Incidences [ Time Frame: Through study completion, an average up to 20 months ]
Central Contacts
- Eledon Pharmaceuticals949-238-8090
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Cincinnati | Cincinnati | Ohio | 45267 | Research Staff |
Find similar trials in Cincinnati, OH
By research site